Author name: lsc-webmaster

CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Chuck Harbert, Ph.D., Chief Scientific Officer of Dyve and additional members of management will be attending the Biotechnology Innovation Organization (BIO) Annual Convention …

Dyve Biosciences to Participate in the BIO International Convention Read More »

Topical application allowing transdermal delivery of DYV702 at the site of the affected joint significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), …

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress Read More »

CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be presenting a corporate overview at the UBS Global Healthcare Conference taking place at …

Dyve Biosciences to Present at the UBS Global Healthcare Conference Read More »

CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be participating in a fireside chat at the 34th Annual Roth Conference in Dana …

Dyve Biosciences to Present at the 34th Annual Roth Conference Read More »

– Former Array BioPharma and Pfizer Executive Joins Dyve Biosciences – CAMARILLO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal drug delivery technology to a broad pipeline of clinical assets, today announced the appointment of Nicholas A. Saccomano, Ph.D., a seasoned biopharmaceutical professional with nearly …

Dyve Biosciences Announces the Appointment of Nicholas A. Saccomano, Ph.D., to its Scientific Advisory Board Read More »

CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that company management will be presenting a corporate overview and participating in one-on-one meetings at the Biocom California Global Life Science Partnering Conference in …

Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference Read More »

CAMARILLO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that company management will be presenting a corporate overview and participating in 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually …

Dyve Biosciences to Present at the 32nd Annual Oppenheimer Healthcare Conference Read More »

Synergestic collaboration will evaluate DYVE’s buffering candidate delivered transdermally for future clinical oncology applications CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer …

Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center Read More »

Two key opinion leaders will discuss gout treatment landscape and perspectives on Phase 2 TARGETS study of DYV702 for the treatment of pain associated with acute gout flares Webinar to be held Tuesday, November 23rd @ 11am ET THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology …

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702 Read More »

THOUSAND OAKS, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors. Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are delighted to have Camilla join our board during this exciting time for Dyve. Our lead …

Dyve Biosciences appoints Camilla V. Simpson to its board Read More »